Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals. Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. “Complementary and Alternative Medicine Treatments” is the fifth of six sections of the 2016 guidelines. Results: Evidence-informed responses were developed for 12 questions for 2 broad categories of complementary and alternative medicine (CAM) interventions: 1) physical and meditative treatments (light therapy, sleep deprivation, exercise, yoga, and acupuncture) and 2) natural health products (St. John’s wort, omega-3 fatty acids; S-adenosyl-L-methionine [SAM-e], dehydroepiandrosterone, folate, Crocus sativus, and others). Recommendations were based on available data on efficacy, tolerability, and safety. Conclusions: For MDD of mild to moderate severity, exercise, light therapy, St. John’s wort, omega-3 fatty acids, SAM-e, and yoga are recommended as first- or second-line treatments. Adjunctive exercise and adjunctive St. John’s wort are second-line recommendations for moderate to severe MDD. Other physical treatments and natural health products have less evidence but may be considered as third-line treatments. CAM treatments are generally well tolerated. Caveats include methodological limitations of studies and paucity of data on long-term outcomes and drug interactions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Light therapy, consisting of daily exposure to bright artificial light, is an evidence-based nonpharmacological treatment for seasonal and nonseasonal major depressive disorder (MDD) that has a low side effect burden and can be used by patients alongside other treatments.”
From Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials (2020) · cites this paper as [14]
In the citing paper
“Light therapy is a recommended first- or second-line treatment for MDD in clinical guidelines 14 based on many clinical studies and meta-analyses. 15,16”
From Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials (2020) · cites this paper as [14]
In the citing paper
“The contrasting statements conveyed by international treatment guidelines preclude drawing definitive conclusions regarding the role of exercise as a treatment for non-severe depression.”
In the citing paper
“Specifically, the use of exercise as an alternative treatment for non-severe depression is endorsed by several treatment guidelines (EPA in Europe, CANMAT in Canada, NICE in the UK and RANZCP in Australia).19–22”
In the citing paper
“Our findings align with the recommendations provided by European, Canadian, Australian and UK treatment guidelines supporting the use of exercise as an alternative treatment for non-severe depression.19–22”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
Cooney, G. M., Dwan, K., Greig, C. A., Lawlor, D. A., Rimer, J., Waugh, F. R., McMurdo, M., & Mead, G. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004366.pub6 · Cited by 1,834
Physical Activity and the Prevention of Depression
Mammen, G., & Faulkner, G. (2013) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2013.08.001 · Cited by 1,122 · cited 1×
“A systematic review of large populationbased, prospective studies suggested that participation in physical activity may also prevent the onset of depression.(47) Further research is therefore needed to assess the long-term benefits of exercise for depression.”
BackgroundSelf-citationTrends in use of complementary and alternative medicine by US adults: 1997-2002.
Tindle, H. A., Davis, R. B., Phillips, R. S., & Eisenberg, D. M. (2005) · PubMed · Cited by 1,099
Cooney, G. M., Dwan, K., Greig, C. A., Lawlor, D. A., Rimer, J., Waugh, F. R., McMurdo, M., & Mead, G. E. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.20.1.2 · Cited by 895
Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709 · cited 1×
“Patients on anticoagulant and antiplatelet medications may also require additional monitoring.(76) Manic induction has been reported in a few cases, although not in bipolar depressed patients.”
BackgroundCramer, H., Lauche, R., Langhorst, J., & Dobos, G. (2013) · Depression and Anxiety · doi:10.1002/da.22166 · Cited by 708 · cited 2×
“Limitations of yoga studies include low quality of RCTs, variability in practice parameters and physical/mental health of participants, as well as difficulties with suitable control conditions.(49) Long-term efficacy and safety data are also lacking.”
BackgroundRosenbaum, S., Tiedemann, A., Sherrington, C., Curtis, J., & Ward, P. B. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08765 · Cited by 692 · cited 2×
“For moderate to severe MDD, 1 meta-analysis (20 trials, N 1⁄4 1298) found exercise to be superior to control conditions.(44) Some methodological challenges, including suitability of control conditions, adequacy of blinding and self-selection bias, may limit interpretation of results.”
BackgroundBrown, R. P., & Gerbarg, P. L. (2005) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2005.11.189 · Cited by 655 · cited 1×
“The proposed neurobiological mechanisms for its benefit include increased turnover of dopamine and gamma-aminobutyric acid (GABA) levels in specific brain regions, regulation of the hypothalamic-pituitaryadrenal axis,(49) and normalization of heart rate variability.(50) The duration of yoga interventions varies, avera…”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 1×
“Light therapy is generally well tolerated,(17) with common side effects being eye strain, headache, agitation, nausea, and sedation.(19) Since 2009, 2 meta-analyses,(16,20) 4 systematic reviews(17,19,21,22) and 3 RCTs(23-25) have been generally confirmatory of recommendations in the 2009 guidelines (see Suppl.”
BackgroundParikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
Self-citationKennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525 · cited 1×
“In 2009, the Canadian Network for Mood and Anxiety Treatments (CANMAT), a not-for-profit scientific and educational organization, published a revision of evidence-based clinical guidelines for the treatment of depressive disorders.(1) CANMAT has updated these guidelines in 2016 to reflect new evidence in the field.”
BackgroundSelf-citationYoga for depression: the research evidence
Pilkington, K., Kirkwood, G., Rampes, H., & Richardson, J. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.08.013 · Cited by 495 · cited 3×
“There are case reports of meditation-induced mania or psychosis and of excessive or incorrect yoga practice possibly contributing to serious adverse effects such as artery occlusion or lotus neuropathy.(48) Yoga continues to be recommended as a second-line adjunctive therapy in mild to moderate MDD with Level 2 Eviden…”
BackgroundInfluentialPhysical exercise intervention in depressive disorders: Meta‐analysis and systematic review
Josefsson, T., Lindwall, M., & Archer, T. (2014) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/sms.12050 · Cited by 483 · cited 1×
“For example, when only high-quality trials were considered, the effect size for benefit of exercise became smaller.(37,42,44) There is also some evidence that exercise has better adherence when supervised by qualified practitioners, so feasibility may be an issue.”
BackgroundSarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.002 · Cited by 469 · cited 2×
“Formulations of SJW have varied widely, as has the dose range (500 to 1800 mg/day), while treatment duration has spanned 4 to 12 weeks.(58,60) Since 2009, 2 systematic reviews(60,61) have confirmed the comparable efficacy of SJW to antidepressants and superiority to placebo for mild to moderate MDD (Suppl.”
BackgroundGrosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449 · cited 1×
“Duration of treatment ranges from 4 to 16 weeks.(70,71) Four new meta-analyses(70-73) and 2 systematic reviews(69,74) have provided updates on the efficacy of o-3 fatty acids in MDD (Suppl.”
BackgroundMeta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression
Sublette, M. E., Ellis, S. P., Geant, A. L., & Mann, J. J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06634 · Cited by 417
Exercise and the treatment of depression: A review of the exercise program variables
Stanton, R., & Reaburn, P. (2014) · Journal of Science and Medicine in Sport · doi:10.1016/j.jsams.2013.03.010 · Cited by 410 · cited 1×
“Recommendations for administration vary, but at least 30 minutes of supervised moderate-intensity exercise at least 3 times weekly for a minimum of 9 weeks is considered effective.(39,40) As with all physical activity interventions, however, the physical fitness of the participant must be taken into consideration.”
BackgroundOmega-3 Fatty Acids and Mood Disorders
Parker, G., Gibson, N. A., Brotchie, H., Heruc, G., Rees, A.-M., & Hadzi-Pavlovic, D. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.6.969 · Cited by 384 · cited 1×
“Manic induction has been reported in a few cases, although not in bipolar depressed patients.(77,78) Thus, o-3 fatty acids have Level 1 Evidence of efficacy but, because of the inconsistency in the evidence, are recommended as second-line monotherapy for mild to moderate MDD and adjunctive to antidepressants for moder…”
Krogh, J., Nordentoft, M., Sterne, J. A. C., & Lawlor, D. A. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04913blu · Cited by 326
Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan
Turner, E. H., Loftis, J. M., & Blackwell, A. D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.004 · Cited by 326 · cited 1×
“The recommended dose in clinical practice is 2 to 4 g/day, with a suggested duration of 3 to 4 months.(85,86) A systematic review(69) and 1 RCT(87) have been published since 2009, with no clear evidence to support an adjunctive role for tryptophan to treat MDD (Suppl.”
BackgroundSmith, C. A., Hay, P. P., & MacPherson, H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004046.pub3 · Cited by 323
Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical Issues
Fava, M., & Mischoulon, D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8157su1c.03 · Cited by 301 · cited 1×
“Genetic polymorphisms may also play a role in efficacy, and certain folate preparations may be better suited to specific genetic profiles.(90) There was no evidence from a meta-analysis (9 trials, N 1⁄4 242) to support the efficacy of inositol as monotherapy or adjunctive therapy in MDD.”
BackgroundBoutron, I., Tubach, F., Giraudeau, B., & Ravaud, P. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.12.010 · Cited by 300 · cited 5×
“The o-3 supplements are generally well tolerated with only mild side effects, including diarrhea, nausea, and a fishy aftertaste.(11,75) Patients on anticoagulant and antiplatelet medications may also require additional monitoring.”
BackgroundInfluentialOmega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch, M. H., & Hannestad, J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.100 · Cited by 293 · cited 1×
“Duration of treatment ranges from 4 to 16 weeks.(70,71) Four new meta-analyses(70-73) and 2 systematic reviews(69,74) have provided updates on the efficacy of o-3 fatty acids in MDD (Suppl.”
BackgroundBorrelli, F., & Izzo, A. A. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9146-8 · Cited by 288 · cited 1×
“In addition, serotonin syndrome and hypomania have been reported when SJW is used concurrently with antidepressants.(67,68) SJW is recommended as first-line monotherapy in mild to moderate MDD (Level 1 Evidence) and is recommended as a second-line adjunctive treatment for moderate to severe MDD (Level 2 Evidence) (Tab…”
BackgroundStubbs, B., Vancampfort, D., Rosenbaum, S., Ward, P. B., Richards, J., Soundy, A., Veronese, N., Solmi, M., & Schuch, F. B. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.019 · Cited by 284 · cited 1×
“There is also some evidence that exercise has better adherence when supervised by qualified practitioners, so feasibility may be an issue.(46) The evidence for the long-term benefits of exercise in MDD is less clear.”
BackgroundPhysical exercise and clinically depressed patients: a systematic review and meta-analysis
Silveira, H., Moraes, H., Oliveira, N., Coutinho, E. S. F., Laks, J., & Deslandes, A. (2013) · Neuropsychobiology · doi:10.1159/000345160 · Cited by 279
Bright-Light Therapy in the Treatment of Mood Disorders
Pail, G., Huf, W., Pjrek, E., Winkler, D., Willeit, M., Praschak-Rieder, N., & Kasper, S. (2011) · Neuropsychobiology · doi:10.1159/000328950 · Cited by 277
Lam, R. W., Levitt, A. J., Levitan, R. D., Michalak, E. E., Cheung, A. H., Morehouse, R., Ramasubbu, R., Yatham, L. N., & Tam, E. M. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2235 · Cited by 275 · cited 1×
“In addition, an RCT reported that LT monotherapy and LT combined with fluoxetine were superior to placebo in nonseasonal MDD, with the combined treatment showing the most consistent effects.(23) Similarly, medication paired with chronotherapeutic techniques (LT, sleep deprivation, and sleep time stabilization) led to…”
BackgroundSelf-citationShelley, B. M., Sussman, A. L., Williams, R. L., Segal, A. R., Crabtree, B. F., & Clinicians, O. B. O. T. R. N. (2009) · The Annals of Family Medicine · doi:10.1370/afm.947 · Cited by 258 · cited 1×
“Such risk is compounded by the fact that patients often do not disclose self-directed CAM use to clinicians,(4,14) and clinicians may not ask.(15) In the absence of adequate safety information on treatment interactions, it is recommended that clinicians discuss the risks and benefits of CAM treatments with their patie…”
BackgroundZhang, Z.-J., Chen, H.-Y., Yip, K.-C., Ng, R., & Wong, V. T. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.07.005 · Cited by 237 · cited 1×
“Sham acupuncture is often used as a control condition; however, there is no robust evidence that any specific acupoints are more relevant to depression than others, and as such, even sham treatment may produce benefits.(57) Small sample sizes, unclear randomization procedures, and heterogeneity of study protocols are…”
BackgroundThe Essential Guide to Herbal Safety
Mills, S. Y., & Bone, K. M. (2005) · EPubDev Repository · Cited by 210
Saffron: a natural product with potential pharmaceutical applications
Christodoulou, E., Kadoglou, N. P., Kostomitsopoulos, N., & Valsami, G. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12456 · Cited by 209 · cited 1×
“sativus (saffron) is 20 to 30 mg/day over 6 to 8 weeks.(95,96) One new meta-analysis (5 trials, N 1⁄4 177)(97) and 3 systematic reviews(96,98,99) further support its use as a monotherapy with comparable efficacy to antidepressants in mild to moderate MDD.”
BackgroundOmega-3 fatty acids for depression in adults
Appleton, K. M., Sallis, H. M., Perry, R., Ness, A. R., & Churchill, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004692.pub4 · Cited by 180
Natural Medicines Comprehensive Database
Hsu, P. P. (2002) · Journal of the Medical Library Association JMLA · Cited by 179
Lopresti, A. L., & Drummond, P. D. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2434 · Cited by 176 · cited 2×
“sativus are mild and include anxiety/nervousness, increased appetite, nausea, and headache.(96) Lavandula (lavender) doses are recommended at 2 to 4.”
BackgroundHausenblas, H. A., Saha, D., Dubyak, P. J., & Anton, S. D. (2013) · Journal of Integrative Medicine · doi:10.3736/jintegrmed2013056 · Cited by 176
Almeida, O. P., Ford, A. H., & Flicker, L. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000046 · Cited by 161 · cited 1×
“A meta-analysis (11 trials, N 1⁄4 2204) of folic acid found no evidence to support its efficacy as a short-term adjunctive agent for antidepressants, although many subjects had medical and other psychiatric comorbidities.(89) However, 2 narrative reviews(90,91) and a retrospective analysis(92) support the use of folat…”
BackgroundMood disorders and complementary and alternative medicine: a literature review
Qureshi, N. A., & Al-Bedah (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s43419 · Cited by 155
Light therapy for non-seasonal depression: systematic review and meta-analysis
Perera, S., Eisen, R., Bhatt, M., Bhatnagar, N., de Souza, R., Thabane, L., & Samaan, Z. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.115.001610 · Cited by 153
The Efficacy of Omega-3 Supplementation for Major Depression: A Randomized Controlled Trial
Lespérance, F., Frasure-Smith, N., St-André, E., Turecki, G., Lespérance, P., & Wisniewski, S. R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m05966blu · Cited by 149 · cited 1×
“The o-3 supplements are generally well tolerated with only mild side effects, including diarrhea, nausea, and a fishy aftertaste.(11,75) Patients on anticoagulant and antiplatelet medications may also require additional monitoring.”
BackgroundChan, Y.-Y., Lo, W.-Y., Yang, S.-N., Chen, Y.-H., & Lin, J.-G. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.048 · Cited by 148
Alkatib, A. A., Cosma, M., Elamin, M. B., Erickson, D., Swiglo, B. A., Erwin, P. J., & Montori, V. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0672 · Cited by 147 · cited 1×
“Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal cortex, which is subsequently converted to sex hormones in the body.(82) It plays a role in modulating neuroendocrine and immune homeostasis and influences monoaminergic and glutaminergic neurotransmission.”
BackgroundAcupuncture and Counselling for Depression in Primary Care: A Randomised Controlled Trial
MacPherson, H., Richmond, S., Bland, M., Brealey, S., Gabe, R., Hopton, A., Keding, A., Lansdown, H., Perren, S., Sculpher, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001518 · Cited by 142
Freeman, M. P., Fava, M., Lake, J., Trivedi, M. H., Wisner, K. L., & Mischoulon, D. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10cs05959blu · Cited by 134 · cited 2×
“evening).(7) The standard protocol is 10,000 lux (light intensity) for 30 minutes per day during the early morning for up to 6 weeks, with response usually seen within 1 to 3 weeks.”
BackgroundKava and St. John's Wort: Current Evidence for Use in Mood and Anxiety Disorders
Sarris, J., & Kavanagh, D. J. (2009) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2009.0066 · Cited by 123 · cited 1×
“There is concern that higher potency extracts can interfere with the metabolism of various medications.(66) In addition, serotonin syndrome and hypomania have been reported when SJW is used concurrently with antidepressants.”
BackgroundRavindran, A. V., & da Silva, T. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.042 · Cited by 121 · cited 1×
“It involves keeping patients awake for extended periods, with total SD lasting up to 40 hours and partial SD allowing 3 to 4 hours of sleep per night.(29) Sleep deprivation is typically employed 2 to 4 times over the course of 1 week, with total SD often interspersed with partial SD or normal (recovery) sleep.”
BackgroundSelf-citationBright white light therapy in depression: A critical review of the evidence
Mårtensson, B., Pettersson, A., Berglund, L., & Ekselius, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.013 · Cited by 120 · cited 1×
“The standard protocol is 10,000 lux (light intensity) for 30 minutes per day during the early morning for up to 6 weeks, with response usually seen within 1 to 3 weeks.(16,17) Proposed mechanisms of antidepressant action include the alteration of circadian rhythms(7) and modulation of serotonin and catecholamine syste…”
BackgroundHerbal medicines, other than St. John's Wort, in the treatment of depression: a systematic review.
Dwyer, A. V., Whitten, D. L., & Hawrelak, J. A. (2011) · PubMed · Cited by 115
Treating Major Depression with Physical Activity: A Systematic Overview with Recommendations
Nyström, M. B. T., Neely, G., Hassmén, P., & Carlbring, P. (2015) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2015.1015440 · Cited by 112 · cited 1×
“Recommendations for administration vary, but at least 30 minutes of supervised moderate-intensity exercise at least 3 times weekly for a minimum of 9 weeks is considered effective.(39,40) As with all physical activity interventions, however, the physical fitness of the participant must be taken into consideration.”
BackgroundMao, J. J., Xie, S. X., Zee, J., Soeller, I., Li, Q. S., Rockwell, K., & Amsterdam, J. D. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.01.010 · Cited by 111
A review of current evidence for acetyl-l-carnitine in the treatment of depression
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.005 · Cited by 110 · cited 2×
“In contrast, a narrative review found that acetylL-carnitine was superior to placebo, and as effective as fluoxetine and amisulpride, as a monotherapy for mild to moderate depression.(94) It is generally well tolerated without significant side effects.”
BackgroundResultAcupuncture for Depression: A Review of Clinical Applications
Wu, J., Yeung, A. S., Schnyer, R., Wang, Y., & Mischoulon, D. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700702 · Cited by 109
Ravindran, A. V., Lam, R. W., Filteau, M. J., Lespérance, F., Kennedy, S. H., Parikh, S. V., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.040 · Cited by 108 · cited 2×
“It is generally well tolerated without significant side effects.(10,94) The usual dose of C.”
BackgroundSelf-citationLam, R. W. M., Kennedy, S. H., Parikh, S. V., MacQUEEN, G. M., Milev, R. V., Ravindran, A. V., & the CANMAT Depression Work Group (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659061 · Cited by 107
Self-citationS-adenosyl-methionine in depression: A comprehensive review of the literature
Papakostas, G. I., Alpert, J. E., & Fava, M. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0085-2 · Cited by 103 · cited 9×
“There is also evidence to support adjunctive SAM-e with antidepressants in mild to moderate MDD.69,81 There are concerns, however, about trial methodologies and paucity of data on SAM-e as maintenance therapy.61 Overall, SAM-e is relatively well tolerated, with the most common side effects being gastrointestinal upset…”
BackgroundInfluentialRahimi, R., Nikfar, S., & Abdollahi, M. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.018 · Cited by 101
Folates and S-Adenosylmethionine for Major Depressive Disorder
Papakostas, G. I., Cassiello, C. F., & Iovieno, N. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700703 · Cited by 99
Sleep Deprivation Therapy for Depression
Dallaspezia, S., & Benedetti, F. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_363 · Cited by 97
Update on the Biology of Seasonal Affective Disorder
Sohn, C.-H., & Lam, R. W. (2005) · CNS Spectrums · doi:10.1017/s109285290001960x · Cited by 96 · cited 1×
“Proposed mechanisms of antidepressant action include the alteration of circadian rhythms(7) and modulation of serotonin and catecholamine systems.(18) Light therapy is generally well tolerated,(17) with common side effects being eye strain, headache, agitation, nausea, and sedation.”
BackgroundSelf-citationSarris, J. J., Kavanagh, D. J., & Byrne, G. J. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.06.003 · Cited by 95 · cited 13×
“It has only been studied as an acute intervention in the short term (4-8 weeks).(69) In 1 RCT, the combination of Lavandula and citalopram was significantly more effective than citalopram alone for moderate to severe depression.”
BackgroundInfluentialSolomon, D., & Adams, J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.031 · Cited by 87 · cited 1×
“Unfortunately, although 10% to 30% of depressed patients are thought to use CAM treatments, there is generally no medical supervision, and these treatments are often used in combination with existing medications without considering possible interactions.(4) As many as 120 different CAM therapies have been identified,(…”
BackgroundMartiny, K., Refsgaard, E., Lund, V., Lunde, M., Sørensen, L., Thougaard, B., Lindberg, L., & Bech, P. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07625 · Cited by 87 · cited 1×
“Similarly, medication paired with chronotherapeutic techniques (LT, sleep deprivation, and sleep time stabilization) led to superior remission rates in nonseasonal MDD compared to medication combined with exercise at both 9-week and 29-week follow-up.(24,27) In summary, the updated evidence continues to support LT as…”
BackgroundA meta‐analysis of inositol for depression and anxiety disorders
Mukai, T., Kishi, T., Matsuda, Y., & Iwata, N. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2369 · Cited by 84 · cited 9×
“There is also evidence to support adjunctive SAM-e with antidepressants in mild to moderate MDD.69,81 There are concerns, however, about trial methodologies and paucity of data on SAM-e as maintenance therapy.61 Overall, SAM-e is relatively well tolerated, with the most common side effects being gastrointestinal upset…”
BackgroundInfluentialExercise in the treatment of major depression: A systematic review grading the quality of evidence
Danielsson, L., Noras, A. M., Waern, M., & Carlsson, J. (2013) · Physiotherapy Theory and Practice · doi:10.3109/09593985.2013.774452 · Cited by 84
Rapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79 · cited 1×
“Several RCTs have demonstrated that an estimated 50% to 75% of SD responders experience continued improvement when SD and SPA are combined.(33) Tripartite interventions (total or partial SD þ light therapy þ SPA) implemented in small open trials also yielded remission rates of 60% to 75%.”
BackgroundChronobiological Therapy for Mood Disorders
Dallaspezia, S., Suzuki, M., & Benedetti, F. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0633-6 · Cited by 76 · cited 2×
“reduction.(36) The risk of SD-induced mania is estimated to be low, with switch rates similar to or lower than with antidepressants and placebo.”
BackgroundChronobiological therapy for mood disorders
Dallaspezia, S., & Benedetti, F. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.61 · Cited by 76
Neuropsychiatric Symptoms and the Use of Complementary and Alternative Medicine
Purohit, M. P., Wells, R. E., ZAFONTE, R. D., Davis, R. B., & Phillips, R. S. (2012) · PM&R · doi:10.1016/j.pmrj.2012.06.012 · Cited by 75
Quah-Smith, I., Smith, C., Crawford, J. D., & Russell, J. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.058 · Cited by 72
Echizenya, M., Suda, H., Takeshima, M., Inomata, Y., & Shimizu, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.022 · Cited by 71 · cited 1×
“Tripartite interventions (total or partial SD þ light therapy þ SPA) implemented in small open trials also yielded remission rates of 60% to 75%.(31,34,35) The most common side effect of SD is daytime sleepiness.”
MethodSahlem, G. L., Kalivas, B., Fox, J. B., Lamb, K., Roper, A., Williams, E. N., Williams, N. R., Korte, J. E., Zuschlag, Z. D., El Sabbagh, S., et al. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.015 · Cited by 71 · cited 1×
“Tripartite interventions (total or partial SD þ light therapy þ SPA) implemented in small open trials also yielded remission rates of 60% to 75%.(31,34,35) The most common side effect of SD is daytime sleepiness.”
MethodA comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.
De Berardis, D., Orsolini, L., Serroni, N., Girinelli, G., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Mazza, M., Valchera, A., Fornaro, M., et al. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150821103825 · Cited by 70 · cited 11×
“There is also evidence to support adjunctive SAM-e with antidepressants in mild to moderate MDD.69,81 There are concerns, however, about trial methodologies and paucity of data on SAM-e as maintenance therapy.61 Overall, SAM-e is relatively well tolerated, with the most common side effects being gastrointestinal upset…”
BackgroundInfluentialRohan, K. J., Mahon, J. N., Evans, M., Ho, S.-Y., Meyerhoff, J., Postolache, T. T., & Vacek, P. M. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101293 · Cited by 68
Second-tier natural antidepressants: Review and critique
Iovieno, N., Dalton, E. D., Fava, M., & Mischoulon, D. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.010 · Cited by 64 · cited 2×
“rosea has mild and infrequent side effects, including nervousness, dizziness, allergy, irritability, insomnia, fatigue, and unpleasant sensations.(102,103) Interactions with concomitant medications, such as theophylline and warfarin, have been reported.”
BackgroundBrattström, A. (2009) · Phytomedicine · doi:10.1016/j.phymed.2008.12.023 · Cited by 62 · cited 1×
“Although SJW is significantly better tolerated than many first-line antidepressants,(64) side effects include gastrointestinal upset, headaches, skin irritation, photosensitivity, and dry mouth.(65) There is concern that higher potency extracts can interfere with the metabolism of various medications.”
BackgroundAn investigation of the contents of complementary and alternative medicine journals.
Coelho, H. F., Pittler, M. H., & Ernst, E. K. (2007) · PubMed · Cited by 60
Clinical Handbook of Psychotropic Drugs
(2017) · Hogrefe Publishing eBooks · doi:10.1027/00496-000 · Cited by 59
Are Tryptophan and 5-Hydroxytryptophan Effective Treatments for Depression? A Meta-Analysis
Shaw, K., Turner, J., & Del Mar, C. (2002) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2002.01046.x · Cited by 59
Ginsberg, L. D., Oubré, A., & Daoud, Y. (2011) · PubMed Central · Cited by 59
Hausenblas, H. A., Heekin, K., Mutchie, H. L., & Anton, S. D. (2015) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(15)60176-5 · Cited by 58
Kasper, S. F., Gastpar, M., Möller, H., Müller, W. E., Volz, H., Dienel, A., & Kieser, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328335dc1a · Cited by 58
Woodward, A. T., Bullard, K. M., Taylor, R. J., Chatters, L. M., Baser, R. E., Perron, B. E., & Jackson, J. S. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.10.1342 · Cited by 58
Rohan, K. J., Meyerhoff, J., Ho, S.-Y., Evans, M., Postolache, T. T., & Vacek, P. M. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060773 · Cited by 55 · cited 1×
“A large RCT also found that cognitive-behavioural therapy (CBT) had similar efficacy to LT as monotherapy or adjunctive in acute treatment of seasonal depression,(25) but a naturalistic follow-up study revealed that CBT was superior after 2 years.(26) Newer studies have expanded the LT evidence base for nonseasonal MD…”
BackgroundThe mechanisms of action of St. John’s wort: an update
Schmidt, M., & Butterweck, V. (2015) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0372-7 · Cited by 54 · cited 1×
“Suggested mechanisms of antidepressant action include direct effect on serotonin receptors, monoamine oxidase inhibition, and neuroendocrine and ion channel modulation.(58,59) Formulations of SJW have varied widely, as has the dose range (500 to 1800 mg/day), while treatment duration has spanned 4 to 12 weeks.”
BackgroundA multistage chronobiologic intervention for the treatment of depression: A pilot study
Moscovici, L., & Kotler, M. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.015 · Cited by 53 · cited 2×
“Sleep deprivation is typically employed 2 to 4 times over the course of 1 week, with total SD often interspersed with partial SD or normal (recovery) sleep.(30,31) Several mechanisms of antidepressant action have been proposed, including increased activity of all neurotransmitter systems, synaptic potentiation, and gl…”
BackgroundMethodLevkovitz, Y., Alpert, J. E., Brintz, C. E., Mischoulon, D., & Papakostas, G. I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.059 · Cited by 51
A systematic review of how homeopathy is represented in conventional and CAM peer reviewed journals
Caulfield, T., & DeBow, S. B. (2005) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-5-12 · Cited by 46
Nikfarjam, M., Parvin, N., Assarzadegan, N., & Asghari, S. (2013) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.4173 · Cited by 45 · cited 2×
“In 1 RCT, the combination of Lavandula and citalopram was significantly more effective than citalopram alone for moderate to severe depression.(101) Adverse effects of Lavandula include nausea, confusion, and mild headaches.”
BackgroundMartiny, K., Refsgaard, E., Lund, V., Lunde, M., Sørensen, L., Thougaard, B., Lindberg, L., & Bech, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067264 · Cited by 43 · cited 1×
“Sleep deprivation is typically employed 2 to 4 times over the course of 1 week, with total SD often interspersed with partial SD or normal (recovery) sleep.(30,31) Several mechanisms of antidepressant action have been proposed, including increased activity of all neurotransmitter systems, synaptic potentiation, and gl…”
BackgroundMannel, M., Kuhn, U., Schmidt, U., Ploch, M., & Murck, H. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.01.010 · Cited by 39 · cited 1×
“In 2 subsequent RCTs, one found no significant difference between SJW, sertraline, or placebo monotherapy,(62) while the other found SJW monotherapy superior to placebo, particularly for individuals with moderate levels of atypical depression.(63) Although SJW is significantly better tolerated than many first-line ant…”
BackgroundStanton, R., Reaburn, P. R. J., & Happell, B. (2013) · Issues in Mental Health Nursing · doi:10.3109/01612840.2013.774077 · Cited by 39 · cited 1×
“While both cardiovascular (aerobic) and resistance (anaerobic) exercise have been shown to be effective in reducing depressive symptoms, there is no clear evidence for the superiority of either form.(38) Recommendations for administration vary, but at least 30 minutes of supervised moderate-intensity exercise at least…”
BackgroundSarris, J. J., D, M. F. M., Schweitzer, I., & Mischoulon, D. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1306348 · Cited by 37
Martiny, K., Refsgaard, E., Lund, V., Lunde, M., Thougaard, B., Lindberg, L., & Bech, P. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12402 · Cited by 37 · cited 1×
“Similarly, medication paired with chronotherapeutic techniques (LT, sleep deprivation, and sleep time stabilization) led to superior remission rates in nonseasonal MDD compared to medication combined with exercise at both 9-week and 29-week follow-up.(24,27) In summary, the updated evidence continues to support LT as…”
BackgroundPanossian, A. G., Hovhannisyan, A., Abrahamyan, H., Gabrielyan, E. S., & Wikman, G. (2008) · Phytotherapy Research · doi:10.1002/ptr.2631 · Cited by 34 · cited 1×
“Interactions with concomitant medications, such as theophylline and warfarin, have been reported.(104) In summary, for mild to moderate MDD, acetylL-carnitine (Level 2 Evidence) is recommended as a third-line monotherapy and C.”
BackgroundNon-Pharmacological Treatment of Depressive Disorders: A Review of Evidence-Based Treatment Options
Dirmaier, J., Steinmann, M., Krattenmacher, T., Watzke, B., Barghaan, D., Koch, U., & Schulz, H. (2012) · Reviews on Recent Clinical Trials · doi:10.2174/157488712800100233 · Cited by 30
Hu, Q., Zhang, S., Liu, F., Zhang, Y., Zhu, D., & Zang, Y. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.051 · Cited by 29 · cited 1×
“It plays a role in modulating neuroendocrine and immune homeostasis and influences monoaminergic and glutaminergic neurotransmission.(83) Dosage of DHEA commonly used in research ranges from 30 to Table 3.”
BackgroundChang, H., Chang, H.-L., & Siren, B. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-319 · Cited by 28
Manipulating melatonin in managing mood
Boyce, P., & Hopwood, M. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12175 · Cited by 27 · cited 1×
“However, combined chronotherapeutic techniques offer rapid onset of efficacy, greater clinical utility, and sustained response compared to total SD alone.(32) One such strategy is the combination of SD with sleep-phase advance (SPA), which involves scheduling bedtimes that are earlier than usual and then advancing the…”
BackgroundJangid, P., Malik, P., Singh, P., Sharma, M., & Gulia, A. (2012) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.05.011 · Cited by 26
Levkovitz, Y., Alpert, J. E., Brintz, C., Mischoulon, D., & Papakostas, G. I. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.03.006 · Cited by 26
Araújo, D. M. R., Vilarim, M. M., & Nardi, A. E. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.77 · Cited by 24
Clinical trials of PUFAs in depression: State of the art
Osher, Y., Belmaker, R. H., & Nemets, B. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600960173 · Cited by 22 · cited 1×
“Manic induction has been reported in a few cases, although not in bipolar depressed patients.(77,78) Thus, o-3 fatty acids have Level 1 Evidence of efficacy but, because of the inconsistency in the evidence, are recommended as second-line monotherapy for mild to moderate MDD and adjunctive to antidepressants for moder…”
Research works printed but not linked: 11
- Tindle HA, 2005, Altern Ther Health Med, 11, 42
- Coelho HF, 2007, Altern Ther Health Med, 13, 40
- Güleç M, 2011, Bull Clin Psychopharm, 21, S89
- Lam RW, 2015, JAMA Psychiatry, 18, 1
- 10.1176/appi.ajp.2015.14101293 · DOI · Paper page
- Cooney GM, 2013, Cochrane Database Syst Rev, 9, CD004366
- Smith CA, 2010, Cochrane Database Syst Rev, 1, CD004046
- Carpenter DJ., 2011, Altern Med Rev, 16, 17
- Appleton KM, 2015, Cochrane Database Syst Rev, 11, CD004692
- Ginsberg LD, 2011, Innov Clin Neurosci, 8, 19
- Dwyer AV, 2011, Altern Med Rev, 16, 40
Cited by
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
“However, the most studied condition associated with acetylcarnitine supplementation is major depressive disorder (MDD), which has been assessed in multiple clinical trials (see Section V).”
MethodInfluentialMorres, I. D., Hatzigeorgiadis, A., Stathi, A., Comoutos, N., Arpin-Cribbie, C., Krommidas, C., & Theodorakis, Y. (2019) · Depression and Anxiety · doi:10.1002/da.22842 · Cited by 350
The Role of Exercise in Preventing and Treating Depression
Schuch, F. B., & Stubbs, B. (2019) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000620 · Cited by 264
Sarris, J., Ravindran, A., Yatham, L. N., Marx, W., Rucklidge, J. J., McIntyre, R. S., Akhondzadeh, S., Benedetti, F., Caneo, C., Cramer, H., et al. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.2013041 · Cited by 216
Self-citationSassarini, D. J. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.09.004 · Cited by 207
Metadata
- Authors
- Ravindran, A. V., Balneaves, L. G., Faulkner, G., Ortiz, A., McIntosh, D., Morehouse, R. L., Ravindran, L., Yatham, L. N., Kennedy, S. H., Lam, R. W., MacQueen, G. M., Milev, R. V., Parikh, S. V., & the CANMAT Depression Work Group
- Affiliations
- University of Toronto (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- Dalhousie University (CA)
- University of Calgary (CA)
- Queen's University (CA)
- ORCID
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2016-08-11
- Volume
- 61
- Issue
- 9
- Pages
- 576-587
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- PMC
- PMC4994794
- OpenAlex
- W2493003628
- Cited by
- 337
- References
- 105
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 43 · 2023: 28 · 2022: 43 · 2021: 39 · 2020: 40 · 2019: 33 · 2018: 30 · 2017: 21 · 2016: 6
- FWCI
- 24.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, adults, complementary and alternative medicine, natural health products, Hypericum perforatum, omega-3 fatty acids, S-adenosylmethionine, dehydroepiandrosterone, folic acid, saffron, phototherapy, sleep deprivation, physical activity, yoga, acupuncture, adjunctive therapy, treatment guidelines
- MeSH terms
- Biological Products, Canada, Major Depressive Disorder, Exercise Therapy, Humans, Phototherapy, Sleep Deprivation, Acupuncture Therapy, Practice Guidelines as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.